Olaparib for Metastatic Castration-Resistant Prostate Cancer

RCT (n=387) found superior progression free survival for olaparib vs abiraterone or enzalutamide (7.4 vs 3.6 months, HR for progression or death 0.34, 95% CI 0.25-0.47) in this population with disease progression while receiving a new hormonal agent.

New England Journal of Medicine